Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 18, 2011, Pages

  Gronich, Naomi ^a   Lavi, Idit ^a   Rennert, Gad ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE; DROSPIRENONE; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISRAEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OBESITY; POPULATION RESEARCH; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 83455236575     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110463     Document Type: Article

References (28)

1. Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004;(350):1-36.
2. Taylor T, Keyse L, Bryant A. Contraception and sexual health, 2005/06. London (UK): National Statistics; 2006.
3. Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011;(5):CD004861.
4. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35. (Pubitemid 32429213)
5. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965-76. (Pubitemid 39390552)
6. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996;348:498-505.
7. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345:1787-93.
8. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
9. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
10. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93. (Pubitemid 26001840)
11. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8.
12. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.
13. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
14. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002;33:1202-8. (Pubitemid 34517036)
15. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
16. Parkin L, Sharples K, Hernandez RK, et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.
17. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation. Contraception 2007;75:344-54. (Pubitemid 46551071)
18. Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93. (Pubitemid 47359582)
19. Bendelac J. Membership in sick funds, 2010. Report 233. Jerusalem (Israel): National Insurance Institute of Israel; 2011. 112 p.
20. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009; 360:2528-35.
21. Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007;167:1533-8. (Pubitemid 47124184)
22. Rosenberg L, Palmer JR, Rao RS, et al. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001;161:1065-70. (Pubitemid 32685532)
23. Goldman MB, Hatch MC. Contraception. In: Women and health. San Diego (CA): Academic Press; 2000. p. 138-59.
24. Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive technology. 19th ed. New York (NY): Ardent Media; 2007.
25. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
26. van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060-2. (Pubitemid 40192767)
27. Junge W, El-Samalouti V, Gerlinger C, et al. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 2009;147:195-200.
28. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6. (Pubitemid 27450823)